Bristol-Myers Squibb (BMY) Tops Q1 EPS by 9c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Bristol-Myers Squibb Reports First Quarter Financial Results
April 26, 2018 6:59 AM EDTIncreases First Quarter Revenues 5% to $5.2 Billion Posts First Quarter GAAP EPS of $0.91 and Non-GAAP EPS of $0.94 Achieves Important Clinical and Regulatory Milestones in Oncology Opdivo plus Yervoy Approved in the U.S. for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma Opdivo Four-Week Dosing Approved in the U.S. and Europe Applications for Opdivo plus Yervoy for Previously Treated Patients with MSI-H or dMMR Metastatic... More
